Literature DB >> 1550668

Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium.

K Amann1, D Greber, H Gharehbaghi, G Wiest, B Lange, U Ganten, T Mattfeldt, G Mall.   

Abstract

Light and electron microscopic stereological studies were performed on the myocardium of spontaneously hypertensive rats (SHR-SP) before and after treatment with nifedipine (27 mg/kg body weight/day) and the antisympathotonic agent moxonidine (8 mg/kg body weight/day). The treated groups were compared with nontreated SHR-SP and normotensive WKY (n = 10 in each group). At the beginning of therapy (when the male SHR-SP were 6 months old), blood pressure was increased and left ventricular hypertrophy had developed whereas pathologic changes of myocardial structure were not observed. After 3 months, the nontreated hypertensive rats showed cardiac fibrosis, activation and proliferation of interstitial cells, wall thickening of intramyocardial arteries, reduced capillarization as well as focal degeneration of myocytes at the ultrastructural level. Both treatments showed similar effects on blood pressure, degree of hypertrophy, and cardiac structure. Blood pressure as well as the degree of hypertrophy were significantly reduced. As far as myocardial fibrosis, capillarization, and regressive changes of myocytes are concerned a complete normalization was observed. Furthermore, nifedipine enhanced capillary supply beyond the normal level by induction of capillary neoformation. Microarteriopathy and activation of nonvascular interstitial cells (first step in development of interstitial myocardial fibrosis) were significantly suppressed by therapy, but the level of the normotensive control could not be maintained. Additional experiments with a low dose combination therapy of nifedipine and moxonidine that did not reduce blood pressure provided evidence that hypertension is an important determinant of the alterations of intramyocardial arteries, but not of cardiac interstitial fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550668     DOI: 10.1093/ajh/5.2.76

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

Review 1.  Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.

Authors:  P Chrisp; D Faulds
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

2.  Causative role of coronary microvessels for the development and progression of chronic myocardial lesions in spontaneously hypertensive rats (SHR).

Authors:  H J Herrmann; P Mühlig
Journal:  Basic Res Cardiol       Date:  1992 Sep-Oct       Impact factor: 17.165

3.  Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation.

Authors:  P-A Paquette; D Duguay; R El-Ayoubi; A Menaouar; B Danalache; J Gutkowska; D DeBlois; S Mukaddam-Daher
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 4.  Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity.

Authors:  Uwe Querfeld; Robert H Mak; Axel Radlach Pries
Journal:  Clin Sci (Lond)       Date:  2020-06-26       Impact factor: 6.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.